KR20150079964A - 효소적 컨쥬게이션에 의한 ｅ．콜라이에서 재조합 백신의 생성 - Google Patents

효소적 컨쥬게이션에 의한 ｅ．콜라이에서 재조합 백신의 생성 Download PDF

Info

Publication number
KR20150079964A
KR20150079964A KR1020157014830A KR20157014830A KR20150079964A KR 20150079964 A KR20150079964 A KR 20150079964A KR 1020157014830 A KR1020157014830 A KR 1020157014830A KR 20157014830 A KR20157014830 A KR 20157014830A KR 20150079964 A KR20150079964 A KR 20150079964A
Authority
KR
South Korea
Prior art keywords
gram
coli
negative bacterium
gene
negative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157014830A
Other languages
English (en)
Korean (ko)
Inventor
미하엘 바커
미하엘 코바리크
미하엘 베터
아미레자 파리드모이어
Original Assignee
글리코박신 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글리코박신 아게 filed Critical 글리코박신 아게
Publication of KR20150079964A publication Critical patent/KR20150079964A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157014830A 2012-11-07 2013-11-07 효소적 컨쥬게이션에 의한 ｅ．콜라이에서 재조합 백신의 생성 Withdrawn KR20150079964A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723408P 2012-11-07 2012-11-07
US61/723,408 2012-11-07
PCT/EP2013/073266 WO2014072405A1 (en) 2012-11-07 2013-11-07 Production of recombinant vaccine in e. coli by enzymatic conjugation

Publications (1)

Publication Number Publication Date
KR20150079964A true KR20150079964A (ko) 2015-07-08

Family

ID=49552366

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157014830A Withdrawn KR20150079964A (ko) 2012-11-07 2013-11-07 효소적 컨쥬게이션에 의한 ｅ．콜라이에서 재조합 백신의 생성

Country Status (16)

Country Link
US (2) US20150273043A1 (enExample)
EP (3) EP2917351B1 (enExample)
JP (2) JP6412875B2 (enExample)
KR (1) KR20150079964A (enExample)
CN (1) CN105008539B (enExample)
AU (2) AU2013343520B2 (enExample)
BR (1) BR112015010283A8 (enExample)
CA (2) CA2889767C (enExample)
EA (1) EA201590705A1 (enExample)
ES (3) ES2882282T3 (enExample)
IL (1) IL238586A0 (enExample)
MX (1) MX366912B (enExample)
SG (1) SG11201503308XA (enExample)
TR (1) TR201903066T4 (enExample)
WO (1) WO2014072405A1 (enExample)
ZA (1) ZA201503097B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2501406T3 (enExample) * 2009-11-19 2018-05-19
BR112016007727A8 (pt) * 2013-10-11 2018-01-30 Glycovaxyn Ag célula hospedeira, e, método para produzir uma proteína n-glicosilada.
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
MX378857B (es) * 2014-04-17 2025-03-10 Glaxosmithkline Biologicals Sa Celulas huespedes modificadas y usos de las mismas.
AR104469A1 (es) 2014-08-08 2017-07-26 Glycovaxyn Ag Células huésped modificadas para su uso en producción de bioconjugados
US10265391B2 (en) * 2015-02-26 2019-04-23 Vaxnewmo Llc Acinetobacter O-oligosaccharyltransferases and uses thereof
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
CN105963691B (zh) * 2016-07-03 2020-05-01 查文娟 一种肺炎链球菌疫苗
CN106929573B (zh) * 2017-02-21 2020-06-09 南开大学 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES
US11235046B2 (en) 2017-11-04 2022-02-01 Nevada Research & Innovation Corporation Immunogenic conjugates and methods of use thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
ES3051337T3 (en) 2018-06-16 2025-12-26 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3650044A1 (en) * 2018-11-06 2020-05-13 ETH Zürich Anti-glycan vaccines
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
CN112369722B (zh) * 2020-05-08 2023-03-17 湖北中烟工业有限责任公司 加热不燃烧装置和温度控制方法
CN111518738B (zh) 2020-05-08 2022-02-08 徐州海润生物科技有限公司 重组卡介苗及其制备方法和应用
CA3185719A1 (en) * 2020-06-18 2021-12-23 Glaxosmithkline Biologicals Sa Shigella-tetravalent (shigella4v) bioconjugate
US20230226175A1 (en) 2020-06-25 2023-07-20 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
EP4452308A1 (en) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2638595A (en) * 1994-05-16 1995-12-05 Uab Research Foundation, The (streptococcus pneumoniae) capsular polysaccharide genes and flanking regions
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
WO2010110931A2 (en) 2009-03-23 2010-09-30 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
JP2012533285A (ja) 2009-07-17 2012-12-27 オーシャン ハーベスト テクノロジー （カナダ） インコーポレイテッド 魚用飼料中の合成添加物を置換する、天然かつ持続可能な海藻配合物
WO2011138361A1 (en) 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
KR20150068998A (ko) * 2012-10-12 2015-06-22 글리코박신 아게 숙주 세포 변형 방법

Also Published As

Publication number Publication date
AU2013343520A1 (en) 2015-06-04
EP2917351A1 (en) 2015-09-16
JP2019030309A (ja) 2019-02-28
EP3508579B1 (en) 2021-06-30
US10973901B2 (en) 2021-04-13
SG11201503308XA (en) 2015-05-28
MX2015005797A (es) 2016-03-09
CN105008539B (zh) 2020-04-17
TR201903066T4 (tr) 2019-03-21
CA3125293A1 (en) 2014-05-15
EP3508579A1 (en) 2019-07-10
EP2917351B1 (en) 2018-12-19
ES2713166T3 (es) 2019-05-20
EP3444352B1 (en) 2020-12-16
CA2889767C (en) 2021-09-21
MX366912B (es) 2019-07-30
JP6833785B2 (ja) 2021-02-24
EP3444352A3 (en) 2019-03-27
IL238586A0 (en) 2015-06-30
ZA201503097B (en) 2018-11-28
WO2014072405A1 (en) 2014-05-15
AU2013343520B2 (en) 2017-09-28
AU2017279688B2 (en) 2019-11-14
US20190076517A1 (en) 2019-03-14
CA2889767A1 (en) 2014-05-15
US20150273043A1 (en) 2015-10-01
CN105008539A (zh) 2015-10-28
BR112015010283A2 (pt) 2017-07-11
EA201590705A1 (ru) 2016-05-31
EP3444352A2 (en) 2019-02-20
ES2848774T3 (es) 2021-08-11
ES2882282T3 (es) 2021-12-01
BR112015010283A8 (pt) 2021-07-06
JP2015533511A (ja) 2015-11-26
JP6412875B2 (ja) 2018-10-24
AU2017279688A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
US10973901B2 (en) Production of recombinant vaccine in E. coli by enzymatic conjugation
US11285200B2 (en) Modified host cells and hybrid oligosaccharides for use in bioconjugate production
TWI751513B (zh) E. coli O-抗原多醣生物結合物、其製備方法及其使用方法
CN107614679B (zh) 用于蛋白糖基化的组合物和方法
JP6682451B2 (ja) 改変型宿主細胞およびその使用
US12350342B2 (en) O-linked glycosylation recognition motifs
CN113950524A (zh) 生产大肠杆菌o-抗原多糖的生物缀合物的方法、其组合物及其使用方法
Yates et al. Bacterial glycoengineering as a biosynthetic route to customized glycomolecules
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150603

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20171228

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid